Length of hospital stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of ICU stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Primary: investigator‐rated good/excellent control of symptoms · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…
Topical calcineurin inhibitors: tacrolimus 0.1% ointment probably leads to higher primary: investigator‐rated good/excellent control of symptoms compared with vehicle (moderate certainty).
1 finding from 1 review
Primary: participant‐rated good/excellent control of symptoms Not measured · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…
The review found no eligible studies for this question.
1 finding from 1 review
Primary: adverse events ‐ burning/itching at application site · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…
Topical calcineurin inhibitors: tacrolimus 0.1% ointment showed no clear difference in primary: adverse events ‐ burning/itching at application site compared with vehicle (moderate certainty).
1 finding from 1 review
Secondary: investigator‐rated reduction in severity ‐ Not measured · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…
The review found no eligible studies for this question.
1 finding from 1 review
Physician's assessment of global response of improvement, clear or excellent ‐ 6 weeks · people with atopic dermatitis
Tacrolimus 0.1% probably leads to higher physician's assessment of global response of improvement, clear or… compared with corticosteroids (moderate certainty).
3 findings from 1 review
RR 3.09 [2.14, 4.45]
1 study · 371 participants
Moderate
RR 0.95 [0.78, 1.16]
1 study · 377 participants
Low
RR 1.32 [1.17, 1.49]
1 study · 972 participants
Moderate
Adverse effects ‐ burning · people with atopic dermatitis
1 finding from 1 review
Participant's self‐assessment of global response of improvement: tacrolimus 0.03% 2x/day versus hydrocortisone acetate 1% 2x/day · people with atopic dermatitis
Tacrolimus 0.03% probably leads to higher participant's self‐assessment of global response of improvement:… compared with corticosteroids (moderate certainty).
1 finding from 1 review
Adverse effects ‐ burning · people with atopic dermatitis
Tacrolimus 0.1% probably leads to higher adverse effects: burning ‐ tacrolimus 0.1% versus hydrocortisone… compared with corticosteroids (moderate certainty).
3 findings from 1 review
RR 2.91 [1.6, 5.28]
1 study · 371 participants
Moderate
RR 4.59 [3.1, 6.78]
1 study · 377 participants
Moderate
RR 3.79 [2.99, 4.81]
1 study · 972 participants
Moderate
Participant's self‐assessment of global response of improvement · people with atopic dermatitis
Tacrolimus 0.1% may leads to higher participant's self‐assessment of global response of improvement compared with corticosteroids (low certainty).
1 finding from 1 review
Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time within 1‐5 weeks) · children and adults with mild to severe eczema
Moderate‐potency probably leads to higher clinician‐reported signs of eczema: IGA (number with cleared or… compared with mild‐potency topical corticosteroid (moderate certainty).
1 finding from 1 review
Patient‐reported symptoms of eczema · children and adults, most with moderate to severe eczema
Potent may leads to lower patient‐reported symptoms of eczema: PGA; short‐term (week 1) compared with moderate‐potency topical corticosteroid (low certainty).
1 finding from 1 review
Local adverse events: skin thinning; end of treatment (1 to 3 weeks) · children and adults, most with moderate to severe eczema
1 finding from 1 review
Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults, most with moderate to severe eczema
1 finding from 1 review
Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time point within 1‐2 weeks) · adults with eczema
Very potent showed no clear difference in clinician‐reported signs of eczema: IGA (number with cleared or… compared with potent topical corticosteroid (low certainty).
1 finding from 1 review
Patient‐reported symptoms of eczema: PGA (number judging excellent); short term (day 8) · adults with eczema
1 finding from 1 review
Local adverse events: skin thinning; end of treatment (1 to 3 weeks) · adults with eczema
It is very uncertain whether very potent changes local adverse events: skin thinning; end of treatment (day 11‐day 22) compared with potent topical corticosteroid (very low certainty).
1 finding from 1 review
Systemic adverse events: abnormal cortisol · adults with eczema
1 finding from 1 review